AMLX Amylyx Pharmaceuticals, Inc.
Stock · NasdaqGS · United States · Healthcare · US03237H1014
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Amylyx Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:27. Information, not advice.
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 04 Mar 2027 08:00 | -0.37 | — | — | Upcoming |
| 05 Nov 2026 07:00 | -0.37 | -0.38 | -2.2% | Miss |
| 06 Aug 2026 07:00 | -0.36 | -0.39 | -9.0% | Miss |
| 07 May 2026 07:00 | -0.34 | -0.37 | -8.7% | Miss |
| 03 Mar 2026 07:00 | -0.34 | -0.30 | +12.2% | Beat |
| 06 Nov 2025 07:00 | -0.43 | -0.37 | +13.9% | Beat |
| 07 Aug 2025 07:00 | -0.45 | -0.46 | -1.2% | Miss |
| 08 May 2025 07:00 | -0.50 | -0.42 | +16.0% | Beat |
| 04 Mar 2025 06:00 | -0.59 | -0.55 | +6.8% | Beat |
| 07 Nov 2024 07:00 | -0.91 | -1.07 | -16.9% | Miss |
| 08 Aug 2024 07:00 | -0.82 | -0.62 | +23.9% | Beat |
| 09 May 2024 07:00 | -0.01 | -0.12 | -1,946.5% | Miss |
| 22 Feb 2024 07:00 | 0.23 | 0.07 | -69.3% | Miss |
| 09 Nov 2023 06:00 | 0.44 | 0.30 | -31.3% | Miss |
| 10 Aug 2023 16:00 | 0.07 | 0.31 | +342.9% | Beat |
| 11 May 2023 16:00 | -0.25 | 0.02 | +108.1% | Beat |
| 13 Mar 2023 16:00 | -0.84 | -0.65 | +22.8% | Beat |
| 10 Nov 2022 16:00 | -0.98 | -0.92 | +5.7% | Beat |
| 11 Aug 2022 16:00 | -0.84 | -0.93 | -10.3% | Miss |
| 12 May 2022 16:00 | -0.69 | -0.93 | -34.8% | Miss |
| 31 Mar 2022 14:00 | -0.64 | -4.15 | -548.4% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | -100.0% | -144.7M | — | -1.53 | +65.5% | -123.5M |
| 2024 | 87.4M | -77.1% | -301.7M | -345.4% | -4.43 | -732.9% | -167.8M |
| 2023 | 380.8M | +1,612.9% | 49.3M | 12.9% | 0.70 | +120.6% | 10.7M |
| 2022 | 22.2M | — | -198.4M | -892.4% | -3.39 | — | -182.4M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Oct 2024 | 3.25 | 5.66 | 2.91 | 5.40 | +66.67% | 36,483,000 | |
| Sep 2024 | 2.23 | 3.34 | 2.08 | 3.24 | +45.95% | 27,352,100 | |
| Aug 2024 | 2.04 | 2.32 | 1.76 | 2.22 | +7.77% | 21,417,600 | |
| Jul 2024 | 1.86 | 2.42 | 1.62 | 2.06 | +8.42% | 42,492,100 | |
| Jun 2024 | 1.73 | 2.10 | 1.58 | 1.90 | +10.47% | 38,108,700 | |
| May 2024 | 1.82 | 2.13 | 1.65 | 1.72 | -4.97% | 30,896,900 | |
| Apr 2024 | 2.84 | 2.89 | 1.70 | 1.81 | -36.27% | 53,129,200 | |
| Mar 2024 | 19.04 | 19.42 | 2.67 | 2.84 | -84.93% | 130,527,900 | |
| Feb 2024 | 16.03 | 19.95 | 14.81 | 18.85 | +17.81% | 27,628,200 | |
| Jan 2024 | 14.72 | 17.06 | 14.35 | 16.00 | +8.70% | 22,856,500 | |
| Dec 2023 | 14.10 | 15.30 | 13.36 | 14.72 | +3.95% | 24,231,000 | |
| Nov 2023 | 16.24 | 18.88 | 11.82 | 14.16 | -13.18% | 42,987,500 | |
| Oct 2023 | 18.30 | 18.49 | 15.61 | 16.31 | -10.92% | 32,865,400 | |
| Sep 2023 | 21.77 | 22.03 | 17.80 | 18.31 | -15.07% | 21,493,600 | |
| Aug 2023 | 23.63 | 23.72 | 19.62 | 21.56 | -8.06% | 27,038,200 | |
| Jul 2023 | 21.70 | 25.48 | 20.03 | 23.45 | +8.72% | 22,593,700 | |
| Jun 2023 | 24.63 | 26.44 | 20.79 | 21.57 | -12.64% | 23,129,200 | |
| May 2023 | 28.40 | 30.50 | 23.50 | 24.69 | -13.06% | 24,937,300 | |
| Apr 2023 | 29.30 | 31.77 | 27.30 | 28.40 | -3.20% | 13,333,300 | |
| Mar 2023 | 35.02 | 38.32 | 26.64 | 29.34 | -15.74% | 27,075,800 | |
| Feb 2023 | 39.19 | 40.88 | 32.67 | 34.82 | -11.15% | 15,197,400 | |
| Jan 2023 | 37.25 | 41.93 | 32.74 | 39.19 | +6.06% | 16,844,500 | |
| Dec 2022 | 38.79 | 39.61 | 32.77 | 36.95 | -3.70% | 16,038,000 | |
| Nov 2022 | 36.07 | 39.78 | 32.69 | 38.37 | +7.57% | 15,919,500 | |
| Oct 2022 | 28.93 | 38.76 | 28.13 | 35.67 | +26.71% | 29,176,500 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Why Amylyx Pharmaceuticals Stock Is Up 6.8% And What's Next (opens in a new tab) Simply Wall St. · 08 Nov 2026 04:27
- Amylyx Pharmaceuticals (AMLX) Stock Looks Pricey After Positive Phase 3 Results (opens in a new tab) Simply Wall St. · 07 Nov 2026 23:12
- Amylyx Pharmaceuticals (AMLX) Posts Positive Phase 3 Data, Is The 30% Discount Justified? (opens in a new tab) Simply Wall St. · 07 Nov 2026 21:15
- Amylyx Pharmaceuticals Inc (AMLX) Q3 2026 Earnings Call Highlights: $768 Million Cash Position ... (opens in a new tab) GuruFocus.com · 07 Nov 2026 19:06
- Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 06 Nov 2026 09:14
- Amylyx Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 05 Nov 2026 23:52
- Amylyx (AMLX) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 19:16
- Amylyx Pharmaceuticals Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 05 Nov 2026 17:14
- Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results (opens in a new tab) 05 Nov 2026 12:00
- Amylyx Pharma Q3 EPS $(0.38), Inline (opens in a new tab) Benzinga · 05 Nov 2026 08:00
- Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts (opens in a new tab) 04 Nov 2026 14:00
- Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences (opens in a new tab) 03 Nov 2026 14:00
- Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 (opens in a new tab) 02 Nov 2026 14:00
- Amylyx Pharmaceuticals And 2 More Quality Growth Stocks (opens in a new tab) Simply Wall St. · 04 Oct 2026 08:09
- Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment (opens in a new tab) MarketBeat · 03 Oct 2026 08:02
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 27.62 USD
- Market cap
- 3.8B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 2.9 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -27.05× | Weak | 14.89× |
| Price / book | 5.03× | Weak | 3.81× |
| EV / EBITDA | -17.27× | Weak | 12.63× |
| Free cash flow yield | -2.1% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 58.6% |
| Operating margin | 0% | Weak | 7.8% |
| Net margin | 0% | Weak | 2.8% |
| Return on equity | -30.1% | Weak | 5.7% |
| Return on assets | -19.1% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 98.3% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.01× | Good | 0.48× |
| Current ratio | 26.81× | Good | 2.39× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow AMLX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.